Chronic Venous Disease, Varicose Veins, Venous Ulcers, and Superficial Interventions
Chronic venous disease as a population-health problem rather than a cosmetic niche: CEAP-classified disease driven by symptoms, skin change, and ulcer history. The chapter frames duplex evaluation, conservative management, superficial venous interventions, and venous ulcer care.
Choose a chapter overview or a specialist discussion. Each recording follows this published edition.
General medical education, not patient-specific advice.
Definition and presentation
Chronic venous disease encompasses a spectrum from uncomplicated visible varicosities to active venous ulceration ( classes C2 to C6). It is highly prevalent; in the Edinburgh Vein Study of adults aged 18 to 64 years, truncal varicose veins were present in 40% of men and 32% of women, while chronic venous insufficiency affected 9% of men and 7% of women, with prevalence rising steeply with age .
Clinical severity and outcome tracking rely on the standardized CEAP classification and the Venous Clinical Severity Score () . Presentation severity, rather than patient age, dictates the necessity of intervention. Presenting features that trigger vascular specialist referral include:
- Symptomatic varicose veins
- Venous skin changes (eczema, hyperpigmentation)
- Superficial vein
- Healed or active leg ulceration
These clinical thresholds separate uncomplicated varicosities from advancing disease requiring duplex mapping and potential intervention .
The clinical (C) axis grades the limb, then annotates each grade with E (etiology), A (anatomy), and P (pathophysiology) .
| Class | Finding |
|---|---|
| C0 | No visible or palpable signs of venous disease |
| C1 | Telangiectasias or reticular veins |
| C2 | Varicose veins (C2r, recurrent) |
| C3 | Edema |
| C4a | Pigmentation or eczema |
| C4b | Lipodermatosclerosis or atrophie blanche |
| C4c | Corona phlebectatica |
| C5 | Healed venous ulcer |
| C6 | Active venous ulcer (C6r, recurrent) |
- Finding
- No visible or palpable signs of venous disease
- Finding
- Telangiectasias or reticular veins
- Finding
- Varicose veins (C2r, recurrent)
- Finding
- Edema
- Finding
- Pigmentation or eczema
- Finding
- Lipodermatosclerosis or atrophie blanche
- Finding
- Corona phlebectatica
- Finding
- Healed venous ulcer
- Finding
- Active venous ulcer (C6r, recurrent)
The 2020 update added the recurrent descriptors C2r and C6r and split C4 to carry C4c corona phlebectatica .
Diagnosis and mapping
Duplex mapping bridges clinical classification and treatment selection by identifying whether symptoms or ulceration correlate with targetable superficial truncal reflux. The assessment isolates great saphenous, small saphenous, or anterior accessory saphenous vein () incompetence from isolated tributary disease. Reflux is timed with the patient standing or in reverse Trendelenburg during distal augmentation: outward flow lasting more than 0.5 s defines pathologic reflux in the superficial trunks (, , AASV, tributaries) and the deep femoral vein, while the femoral and popliteal veins require reflux longer than 1.0 s. A perforator is incompetent when outward flow exceeds 0.5 s and its diameter is 3.5 mm or greater . Modality selection relies on this anatomic map; outcomes specifically for AASV insufficiency treated with endovenous laser ablation () demonstrate that non-great-saphenous targets require distinct consideration .
When clinical severity, extreme swelling, or ulcer behavior is disproportionate to the mapped superficial reflux, the diagnostic focus broadens to assess deep venous obstruction or pelvic and splanchnic reflux sources .
Medical and conservative therapy
Compression is central to venous ulcer care; compared with no compression, bandages or stockings probably shorten healing time and increase the proportion of healed ulcers .
VenUS IV randomized 457 patients with venous ulcers, at least 0.8 and tolerance of high compression to two-layer hosiery or four-layer bandaging. Median healing times were 99 and 98 days, respectively; more patients assigned hosiery changed treatment. This comparison does not establish equivalence of all compression pressures or products . Assess arterial perfusion before sustained compression. For active venous ulcers with adequate perfusion, ESVS recommends multicomponent, inelastic or adjustable compression targeting at least 40 mmHg at the ankle (I/A). Sustained compression is not recommended if ankle pressure is below 60 mmHg, toe pressure below 30 mmHg, or ABI below 0.6 (III/C). Modified compression for mixed disease requires close supervision .
For ulcer recurrence prevention, higher-compression hosiery (European or UK class 3) is more effective than lower compression or no compression. However, class 2 compression is better tolerated, making patient adherence the primary determinant of long-term success .
Adjunctive pharmacotherapy is indicated for selected venous ulcer patients. Pentoxifylline 400 mg three times daily combined with compression improves complete ulcer healing rates compared to placebo plus compression (relative risk 1.56; 95% confidence interval 1.14–2.13), though gastrointestinal upset is a common limitation . Sulodexide, an oral glycosaminoglycan, also demonstrates efficacy as an adjunctive therapy for venous leg ulcer healing .
Treatment decision and intervention
Intervention requires symptoms or complications attributable to mapped reflux, not visible veins alone. For eligible patients with symptomatic GSV or SSV axial reflux, SVS/AVF/AVLS recommends intervention over long-term stockings (1/B) and suggests against requiring a three-month stocking trial first (2/B) .
Endovenous laser or radiofrequency
- Practical distinction
- Thermal truncal closure; requires perivenous tumescence
- Evidence boundary
- Endovenous treatment is preferred to stripping for suitable symptomatic GSV reflux (1/B)
Ultrasound-guided foam
- Practical distinction
- Useful when a catheter-based truncal approach is unsuitable or for selected tributaries
- Evidence boundary
- Long-term recurrence and quality-of-life priorities can favor thermal treatment or surgery over physician-compounded foam (2/B)
Mechanochemical ablation
- Practical distinction
- Nonthermal option combining mechanical injury with sclerosant
- Evidence boundary
- A small randomized comparison exists; its 12-month results do not establish five-year equivalence
Cyanoacrylate closure
- Practical distinction
- Adhesive, nonthermal truncal closure
- Evidence boundary
- VeClose provides five-year extension data, but substantial attrition limits inference
Stripping or phlebectomy
- Practical distinction
- Surgical treatment of the appropriate truncal or tributary target
- Evidence boundary
- Anatomy, local expertise and patient preference determine suitability; surgery remains an option when endovenous treatment is unsuitable
CHIVA is a distinct hemodynamic, vein-preserving strategy, not another method of truncal ablation; it requires its own reflux assessment and expertise .
Age alone is not an exclusion criterion for intervention. Patients older than 70 years achieve clinically meaningful quality-of-life and symptom improvements following endovenous ablation comparable to younger cohorts; frailty and life expectancy govern the decision .
Symptomatic varicosities
- Clinical condition
- Truncal reflux confirmed
- Preferred action
- Endothermal ablation first-line; foam sclerotherapy second-line; surgery third-line
CitationActive venous ulcer
- Clinical condition
- Superficial reflux contributes to ulceration
- Preferred action
- Assess for early ablation plus compression; the EVRA trial’s ulcer-duration entry criterion is not a universal exclusion rule for older ulcers
CitationOlder adults
- Clinical condition
- Age > 70 years with symptomatic disease
- Preferred action
- Intervention based on frailty and life expectancy, not chronological age
Citation
The stepwise logic for procedural intervention is:
- Confirm that symptoms or ulceration correlate with a treatable reflux source.
- Assess arterial perfusion, deep venous disease and procedural suitability.
- Discuss ablation with compression for active venous ulceration; do not deny assessment solely because ulcer duration exceeds the EVRA enrollment window.
- Select a thermal, nonthermal or surgical approach for the mapped target.
- Use conservative care when intervention is unsuitable or is not the patient’s preference; a compulsory stocking trial is not required before otherwise appropriate intervention .
Follow-up and complications
Post-procedural surveillance relies on standardized VCSS documentation to track symptom resolution, skin changes, and ulcer healing. Surveillance intervals track symptom and wound response rather than a fixed calendar, with reassessment guided by clinical severity scoring . Superficial venous surgery and endovenous correction of reflux decrease long-term ulcer recurrence rates . ESCHAR quantified the prevention benefit: adding superficial reflux surgery to compression left 24-week healing unchanged (65% versus 65%) but cut 12-month ulcer recurrence from 28% to 12%.
Post-ablation complication screening specifically evaluates for endothermal heat-induced thrombosis (). The EHIT consensus terminology dictates complication categorization and subsequent management pathways, distinguishing transient post-procedural phenomena from clinically significant thrombosis .
The AVF/SVS scheme grades thrombus extension at the saphenous junction and drives treatment .
| Class | Extent | Management |
|---|---|---|
| 1 | Thrombus at the junction, not into the deep vein | No treatment |
| 2 | Extension into the deep vein, under 50% of its lumen | Surveillance, antiplatelet or short-course anticoagulation until retraction |
| 3 | Extension 50% or more of the deep-vein lumen | Therapeutic anticoagulation with serial duplex |
- Extent
- Thrombus at the junction, not into the deep vein
- Management
- No treatment
- Extent
- Extension into the deep vein, under 50% of its lumen
- Management
- Surveillance, antiplatelet or short-course anticoagulation until retraction
- Extent
- Extension 50% or more of the deep-vein lumen
- Management
- Therapeutic anticoagulation with serial duplex
Areas of controversy
- Long-term durability of non-thermal modalities: While thermal ablation, foam, mechanochemical ablation, and cyanoacrylate closure demonstrate definitive early efficacy, comparative recurrence data beyond five years remain sparse, and evidence certainty across modalities ranges from low to moderate .
- Early ablation in chronic or complex ulcers: The EVRA trial robustly supports early superficial ablation for venous ulcers of less than 6 months duration, but the degree of benefit in long-standing, complex, or mixed-etiology ulcers remains less defined .
Further reading
- Interventions for great saphenous vein incompetence. (2021). Great-saphenous reflux intervention comparison.
- Compression for preventing recurrence of venous ulcers. (2024). Compression and recurrent venous ulcer prevention.
References
- 1.Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. 1999.PubMed-indexed articleRegistry / cohort1999
Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. 1999. doi:10.1136/jech.53.3.149.
- 2.
- 3.Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. 2010.PubMed-indexed articleClinical practice guideline2010
Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. 2010. doi:10.1016/j.jvs.2010.06.161. PMID:20875713.
- 4.Diagnosis and management of varicose veins in the legs: summary of NICE guidance.PubMed-indexed article2013
Marsden G, Perry M, Kelley K, Davies AH, Guideline Development Group. Diagnosis and management of varicose veins in the legs: summary of NICE guidance. BMJ. 2013;347:f4279. doi:10.1136/bmj.f4279. PMID:23884969.
- 5.The 2022 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part I. Duplex Scanning and Treatment of Superficial Truncal Reflux: Endorsed by the Society for Vascular Medicine and the International Union of Phlebology. 2023.PubMed-indexed articleClinical practice guideline2022
The 2022 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part I. Duplex Scanning and Treatment of Superficial Truncal Reflux: Endorsed by the Society for Vascular Medicine and the International Union of Phlebology. 2023. doi:10.1016/j.jvsv.2022.09.004. PMID:36326210.
- 6.The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II. 2024.PubMed-indexed articleClinical practice guideline2023
The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II. 2024. doi:10.1016/j.jvsv.2023.08.011.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. 2011.PubMed-indexed articleRandomized controlled trial2011
Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. 2011. doi:10.1002/bjs.7555. PMID:21725957.
- 16.Laser ablation versus mechanochemical ablation in the treatment of primary varicose veins: A randomized clinical trial. 2020.PubMed-indexed articleRandomized controlled trial2020
Laser ablation versus mechanochemical ablation in the treatment of primary varicose veins: A randomized clinical trial. 2020. doi:10.1016/j.jvsv.2019.10.025. PMID:31864932.
- 17.Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. 2020.PubMed-indexed articleRandomized controlled trial2020
Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. 2020. doi:10.1016/j.jvsv.2019.12.080. PMID:32205125.
- 18.
- 19.Age is not a barrier to good outcomes after varicose vein procedures.No stable evidence linkRegistry / cohort2017
- 20.
- 21.
- 22.Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial.PubMed-indexed articleRandomized controlled trial2004
Barwell JR, Davies CE, Deacon J, Harvey K, Minor J, Sassano A, et al. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. Lancet. 2004;363(9424):1854-9. doi:10.1016/S0140-6736(04)16353-8. PMID:15183623.
- 23.
- 24.
- 25.Clinical and cost-effectiveness of compression hosiery versus compression bandages in treatment of venous leg ulcers (Venous leg Ulcer Study IV, VenUS IV): a randomised controlled trial 2014.PubMed-indexed article2014
Clinical and cost-effectiveness of compression hosiery versus compression bandages in treatment of venous leg ulcers (Venous leg Ulcer Study IV, VenUS IV): a randomised controlled trial 2014. doi:10.1016/S0140-6736(13)62368-5.
Educational use only
AI assists this editorial workflow. Published updates are human-reviewed before publication.
Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.
Verify clinically relevant information against primary sources and current guidelines.